Advanced Parkinson's DiseasePhase 3NCT01736176
A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease
A Phase 3 study testing Levodopa-Carbidopa Intestinal Gel, Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J) and Levodopa-carbidopa Immediate Release (LC-IR) Tablets in people with Advanced Parkinson's Disease, run by AbbVie (prior sponsor, Abbott).
Trial summary
The primary objective of this study is to evaluate change in non-motor symptoms from baseline to Week 12 as measured by the Non-Motor Symptom Scale total score. Read more about this study
- Who is it for?
- Ages 30 years and older
- Conditions the study is for
- Advanced Parkinson's Disease
- What is being tested?
- Levodopa-Carbidopa Intestinal Gel, Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J) and Levodopa-carbidopa Immediate Release (LC-IR) Tablets
- Type of treatment
- Pill or oral medicine, Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 39 participants
- Where
- No sites listed yet
- Study dates
- Mar 2013to Dec 2015
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject must have a diagnosis of idiopathic Parkinson's disease (PD) according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria
- Demonstrate persistent motor fluctuations in spite of individually optimized treatment
- Subject must experience a minimum of 3 hours "Off" time
Who cannot join
- Subject's PD diagnosis is unclear or there is a suspicion that the subject has a Parkinsonian syndrome such as secondary Parkinsonism (e.g., caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), Parkinson-plus syndrome (e.g., Multiple System Atrophy, Progressive Supranuclear Palsy, Diffuse Lewy Body Disease, Corticobasilar Degeneration), or other neurodegenerative disease that might mimic the symptoms of PD.
- Subject has undergone neurosurgery for the treatment of Parkinson's disease
- Subject for whom the placement of a PEG-J tube for LCIG treatment is contraindicated or is considered a high risk for the PEG-J procedure according to the gastroenterology evaluation (e.g., pathological changes of the gastric wall, inability to bring the gastric wall and abdominal wall together, blood coagulation disorders, peritonitis, acute pancreatitis, paralytic ileus).
About this study
Official title: An Open-Label, Two Part, Multicenter Study to Assess the Safety and Efficacy of Levodopa-Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects With Advanced Parkinson's Disease
The primary objective of this study is to evaluate change in non-motor symptoms from baseline to Week 12 as measured by the Non-Motor Symptom Scale total score.
- Conditions
- Advanced Parkinson's Disease
- Being tested
- Levodopa-Carbidopa Intestinal Gel, Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J), Levodopa-carbidopa Immediate Release (LC-IR) Tablets
- Keywords
- Safety and efficacy, Advanced Parkinson's disease, levodopa-carbidopa intestinal gel,, carbidopa, levodopa, Non-Motor Symptom Scale
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Levodopa-Carbidopa Intestinal GelDrug
Also called Duopa, Carbidopa-levodopa enteral suspension (CLES)
Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.
The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours.
Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)Procedure or surgery
Levodopa-carbidopa Immediate Release (LC-IR) TabletsDrug
After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
| Study group | Role | What they receive |
|---|---|---|
| Levodopa-Carbidopa Intestinal Gel | Experimental | Participants had the PEG-J tube placement procedure performed on Study Day 1 and, at the discretion of the investigator, began initiation and titration of LCIG infusion. Dosing was determined individually. The starting total daily dose of LCIG was based solely on the daily dose of the oral levodopa taken immediately prior to Study Day 1 and was adjusted to obtain the optimal clinical response for the individual participant.
Participants received treatment for up to 60 weeks; participants who completed their Week 60 visit before LCIG was commercially available had the option to extend their LCIG therapy, if in the opinion of the investigator, the participant would benefit from continued LCIG treatment. Receives: Drug: Levodopa-Carbidopa Intestinal Gel; Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J); Drug: Levodopa-carbidopa Immediate Release (LC-IR) Tablets |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline to Week 12 in the Non-Motor Symptom Scale (NMSS) Total Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent).
Item scores are calculated as the product of severity and frequency; the total score is obtained by summing the item scores. The NMSS total score ranges from 0 to 360 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Measured: Baseline and Week 12
Secondary outcomes (37)
Number of Participants Who Used Healthcare Resources During the First 4 Weeks
Use of healthcare resources was assessed by the investigator using the Health Resource Utilization Questionnaire (HRUQ), a questionnaire developed by the Sponsor regarding the use of healthcare resources due to the participant's Parkinson's disease. The Week 4 version of the questionnaire addressed the following questions during the first four weeks after the PEG-J procedure:
- Has the subject had a visit to an emergency room?
- Has the subject had a visit to an urgent care?
- Has the subject had an outpatient visit to a neurologist?
- Has the subject had an outpatient visit to a gastroenterologist, surgeon, or interventional radiologist?
- Has the subject had an outpatient visit to a primary care physician?
- Has the subject called the nursing support line?
- Has the subject called a physician?
Measured: Weeks 1-4
Number of Participants With Adverse Events
Adverse events (AEs) related to treatment are those the investigator determined as having a reasonable possibility being related to study drug based on evidence to suggest a causal relationship between the study drug and the adverse event.
A severe AE was defined as an adverse event that caused considerable interference with the participant's usual activities and might be incapacitating or life-threatening.
Serious AEs were defined as those that were life-threatening or resulted in death, hospitalization or prolongation of hospitalization, a congenital anomaly, persistent or significant disability/incapacity, or important medical events requiring medical or surgical intervention to prevent a serious outcome.
Measured: Weeks 1-4 and Overall (from Week 1 through 30 days after the end of the LCIG Treatment Period; median duration of LCIG device exposure was 428 days)
Number of Participants Who Used Healthcare Resources Through Week 60
Use of healthcare resources was assessed by the investigator using the Health Resource Utilization Questionnaire (HRUQ), a questionnaire developed by the Sponsor regarding the use of healthcare resources due to the participant's Parkinson's disease. The standard version of the questionnaire addressed the following questions over the last 3 months:
- Has the subject had a visit to an emergency room?
- Has the subject had an outpatient visit to any of the following healthcare providers?
- Has the subject been visited in his or her place of residence by a health care professional?
- Has the subject received assistance from either of the following for their Parkinson's disease in their home?
- Has the subject needed to contact either of the following for immediate assistance related to their Parkinson's disease?
- Have family members or friends had to miss any paid work due to the subject's Parkinson's disease?
- Has the subject fallen during the past month?
Measured: Week 60
Change From Baseline to Week 60 in the Non-Motor Symptom Scale (NMSS) Total Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent).
Item scores are calculated as the product of severity and frequency; the total score is obtained by summing the item scores. The NMSS total score ranges from 0 to 360 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Measured: Baseline and Week 60
Change From Baseline in NMSS Cardiovascular Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent).
Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS cardiovascular including falls domain score ranges from 0 to 24 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Sleep/Fatigue Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent).
Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS sleep/fatigue domain score ranges from 0 to 48 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Mood/Cognition Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent).
Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS mood/cognition domain score ranges from 0 to 72 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Perceptual Problems/Hallucinations Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent).
Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS perceptual problems/hallucinations domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Attention/Memory Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent).
Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS attention/memory domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Gastrointestinal Tract Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent).
Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS gastrointestinal tract domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Urinary Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent).
Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS urinary domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Sexual Function Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent).
Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS sexual function domain score ranges from 0 to 24 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Miscellaneous Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent).
Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS miscellaneous domain score ranges from 0 to 48 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in Mean Daily Normalized "Off" Time Based on Parkinson's Disease Diary
The Parkinson's Disease Diary was completed by the participant for 3 consecutive days prior to each visit for the full 24 hours of each day. Participants recorded whether they had been "On," "Off," or "Asleep" and the severity of their dyskinesias (troublesome or not troublesome) for each 30-minute period during their normal waking time and upon awakening from time asleep.
"Off" time was defined as time when medication has worn off and was no longer providing benefit with regard to mobility, slowness, and stiffness.
Parkinson's Disease Diary times were normalized to a 16-hour waking time to account for variation in participants' sleep time. Normalized PD Diary times at a given visit were calculated as the average normalized time from the PD Diary for the 3 days prior to the visit.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in Mean Daily Normalized "On" Time Without Troublesome Dyskinesia Based on PD Diary
The PD Diary was completed by the participant for 3 consecutive days prior to each visit. Participants recorded whether they had been "On," "Off," or "Asleep" and the severity of their dyskinesias (troublesome or not troublesome) for each 30-minute period during their normal waking time and upon awakening from sleep.
"On" was defined as time when medication was providing benefit with regard to mobility, slowness, and stiffness. "On" time without troublesome dyskinesia is a composite of "On" time without dyskinesia (involuntary twisting, turning movements which are an effect of medication) plus "On" time with non-troublesome dyskinesia (dyskinesia that does not interfere with function or cause meaningful discomfort).
PD Diary times were normalized to a 16-hour waking time to account for variation in participants' sleep time. Normalized PD Diary times at a given visit were calculated as the average normalized time from the PD Diary for the 3 days prior to the visit.
Measured: Baseline and Week 12 and Week 60
Change From Baseline for Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater.
The UPDRS was made up of the following sections:
- Part I - Mentation, Behavior, and Mood
- Part II - Activities of Daily Living
- Part III - Motor Examination
- Part IV - Complications of Therapy (including dyskinesias)
- Part V - Modified Hoehn and Yahr Staging
The Total UPDRS score includes 31 items contributing to three subscales: (I) Mentation, Behavior, and Mood; (II) Activities of Daily Living; and (III) Motor Examination. Each question is answered on a scale from 0 (None) to 4 (Severe); Some questions require multiple grades assigned to each extremity. The UPDRS Total score was computed as the sum of these 3 UPDRS subscales and ranged from 0 to 176, with 176 representing the worst (total) disability, and 0 no disability.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Part I: Mentation, Behavior, and Mood Score
The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater.
The UPDRS was made up of the following sections:
- Part I - Mentation, Behavior, and Mood
- Part II - Activities of Daily Living
- Part III - Motor Examination
- Part IV - Complications of Therapy (including dyskinesias)
- Part V - Modified Hoehn and Yahr Staging
The mentation, behavior, and mood score includes 4 items addressing intellectual impairment, thought disorder, motivation/initiative, and depression. Each question is answered on a scale from 0 (None) to 4 (Severe). The UPDRS Part I: mentation, behavior, and mood score was computed as the sum of these items and ranged from 0 (not affected) to 16 (most severely affected).
Measured: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Part II: Activities of Daily Living (ADL) Score
The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater.
The UPDRS was made up of the following sections:
- Part I - Mentation, Behavior, and Mood
- Part II - Activities of Daily Living
- Part III - Motor Examination
- Part IV - Complications of Therapy (including dyskinesias)
- Part V - Modified Hoehn and Yahr Staging
The activities of daily living score includes 13 items addressing speech, salivation, swallowing, handwriting, cutting food, dressing, hygiene, turning in bed, falling, freezing, walking, tremor, and sensory complaints. Each question is answered on a scale from 0 (Normal) to 4 (Severe). The UPDRS Part II: activities of daily living score was computed as the sum of these items and ranged from 0 (not affected) to 52 (most severely affected).
Measured: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Part III: Motor Examination Score
The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater.
The UPDRS was made up of the following sections:
- Part I - Mentation, Behavior, and Mood
- Part II - Activities of Daily Living
- Part III - Motor Examination
- Part IV - Complications of Therapy (including dyskinesias)
- Part V - Modified Hoehn and Yahr Staging
The motor examination score includes 17 items addressing speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. Each question is answered on a scale from 0 (Normal) to 4 (Severe), some items include multiple grades for each extremity. The UPDRS Part III: motor examination score was computed as the sum of these items and ranged from 0 (not affected) to 108 (most severely affected).
Measured: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Part IV: Complications of Therapy Score
The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater.
The UPDRS was made up of the following sections:
- Part I - Mentation, Behavior, and Mood
- Part II - Activities of Daily Living
- Part III - Motor Examination
- Part IV - Complications of Therapy (including dyskinesias)
- Part V - Modified Hoehn and Yahr Staging
The complications of therapy section includes 11 items addressing dyskinesia duration, disability, and pain, early morning dystonia, "offs"-predictable, "offs"-unpredictable, "offs"-sudden, "offs"-duration, anorexia-nausea-vomiting, sleep disturbance, and symptomatic orthostasis. Four questions are answered on a scale from 0 (Normal) to 4 (Severe) and seven on a binary scale where 0=No and 1=Yes. The UPDRS Part IV: complications of therapy score was computed as the sum of these items and ranged from 0 (not affected) to 23 (most severely affected).
Measured: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Dyskinesia Items Score
The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater.
The UPDRS was made up of the following sections:
- Part I - Mentation, Behavior, and Mood
- Part II - Activities of Daily Living
- Part III - Motor Examination
- Part IV - Complications of Therapy (including dyskinesias)
- Part V - Modified Hoehn and Yahr Staging
The dyskinesia items score includes questions 32, 33 and 34 from the complications of therapy section of the UPDRS which address dyskinesia duration, disability, and pain. Each question was answered on a scale from 0 (Normal) to 4 (Severe); the UPDRS dyskinesia items score was computed as the sum of these items and ranged from 0 (not affected) to 12 (most severely affected).
Measured: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Part V: Modified Hoehn and Yahr Staging Score
The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater.
The UPDRS was made up of the following sections:
- Part I - Mentation, Behavior, and Mood
- Part II - Activities of Daily Living
- Part III - Motor Examination
- Part IV - Complications of Therapy (including dyskinesias)
- Part V - Modified Hoehn and Yahr Staging
The modified Hoehn and Yahr scale is as follows:
- Stage 0: No signs of disease
- Stage 1.0: Symptoms are very mild; unilateral involvement only
- Stage 1.5: Unilateral and axial involvement
- Stage 2: Bilateral involvement without impairment of balance
- Stage 2.5: Mild bilateral disease with recovery on pull test
- Stage 3: Mild to moderate bilateral disease; some postural instability; physically independent
- Stage 4: Severe disability; still able to walk or stand unassisted
- Stage 5: Wheelchair bound or bedridden unless aided
Measured: Baseline and Week 12 and Week 60
Change From Baseline in Parkinson's Disease Questionnaire-39 Item (PDQ-39) Summary Index
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility [10 items], activities of daily living [six items], emotional wellbeing [six items], stigma [four items], communication [three items] and bodily discomfort [three items]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable).
The PDQ-39 Summary Index (PDQ-SI) is the sum of all answers divided by the highest score possible (i.e., number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0 - 100 scale where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Mobility Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility [10 items], activities of daily living [six items], emotional wellbeing [six items], stigma [four items], communication [three items] and bodily discomfort [three items]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable).
Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Activities of Daily Living Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility [10 items], activities of daily living [six items], emotional wellbeing [six items], stigma [four items], communication [three items] and bodily discomfort [three items]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable).
Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Emotional Well-Being Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility [10 items], activities of daily living [six items], emotional wellbeing [six items], stigma [four items], communication [three items] and bodily discomfort [three items]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable).
Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Stigma Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility [10 items], activities of daily living [six items], emotional wellbeing [six items], stigma [four items], communication [three items] and bodily discomfort [three items]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable).
Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Social Support Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility [10 items], activities of daily living [six items], emotional wellbeing [six items], stigma [four items], communication [three items] and bodily discomfort [three items]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable).
Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Cognition Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility [10 items], activities of daily living [six items], emotional wellbeing [six items], stigma [four items], communication [three items] and bodily discomfort [three items]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable).
Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Communication Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility [10 items], activities of daily living [six items], emotional wellbeing [six items], stigma [four items], communication [three items] and bodily discomfort [three items]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable).
Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Measured: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Bodily Discomfort Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility [10 items], activities of daily living [six items], emotional wellbeing [six items], stigma [four items], communication [three items] and bodily discomfort [three items]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable).
Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Measured: Baseline and Week 12 and Week 60
Percentage of Participants With a Patient Global Impression of Change (PGIC) Response of Improved
The PGIC is a 7-point response scale. Participants were asked to rate their change in status using the following 7-point scale:
1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse.
The responses of "Very much improved," "Much improved" and "Minimally improved" on the PGIC were used to define responders.
Measured: Week 12 and Week 60
Treatment Satisfaction Questionnaire Scores
The Treatment Satisfaction Questionnaire (TSQ) is a single item instrument developed by the Sponsor on which the participant indicated their level of satisfaction or dissatisfaction with their PD treatment. The responses are recorded on a Likert-type scale (Very Satisfied, Satisfied, Somewhat Satisfied, Somewhat Dissatisfied, Dissatisfied, Very Dissatisfied).
Measured: Week 12 and Week 60
Change From Baseline in Health-related Productivity
The Health-Related Productivity Questionnaire (HRPQ) is a generic measure of the impact of disease on the ability of the participant to be productive at paid employment or at performance of household chores. Questions inquire about the amount of time they were scheduled/planned to work, the number of the scheduled/planned hours they were able to work and their ability to be productive for the hours of work they did perform.
Absenteeism: Number of hours not worked due to PD or it's treatments;
Presenteeism: Number of hours of lost productivity while at work due to PD or it's treatments;
Total hours lost: Number of hours lost due to absenteeism and presenteeism
Measured: Baseline, Week 12 and Week 60
Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Spatial Working Memory Between Errors Score at Week 12
CANTAB is a computer-based test of the participant's ability to retain spatial information and to manipulate remembered items in working memory. The Spatial Working Memory module requires that subjects find a blue token in a series of displayed boxes and use these to fill up an empty column, while not returning to boxes where a blue token has been previously found. The between errors score is the number of times the participant revisited a box in which a token was previously found; errors are calculated for 4-, 6-, and 8-box trials. Higher numbers indicate poorer performance.
Measured: Baseline and Week 12
Change From Baseline in CANTAB Spatial Working Memory Strategy Score at Week 12
CANTAB is a computer-based test of the participant's ability to retain spatial information and to manipulate remembered items in working memory. The Spatial Working Memory module requires that subjects find a blue token in a series of displayed boxes and use these to fill up an empty column, while not returning to boxes where a blue token has been previously found. The Strategy score represents the number of times a participant begins a search with the same box for 6- and 8-box problems. Minimum score is 8 and maximum score is 56. Higher numbers indicate poorer performance.
Measured: Baseline and Week 12
Change From Baseline in Controlled Oral Word Association Test (COWAT) Verbal Fluency Scores at Week 60
Letter fluency was assessed using a paper and pen test, in which participants were asked to generate as many words as possible in 60 seconds, starting with the letters F, A, or S.
The COWAT All Letters score is the number of words recalled in all post-baseline assessments, regardless of letter used.
The COWAT Baseline Letter score is the number of words recalled in post-baseline assessments that used the same letter as at Baseline.
Measured: Baseline and Week 60
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Nov 2012 (estimated)
- Study startMar 2013
- Primary completionMar 2015
- Study completionDec 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Advanced Parkinson's DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 39 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Janet Benesh, BS, Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01736176
- Sponsor's protocol ID
- M12-920
- Status last verified
- Jul 2021
- First submitted
- 27 Nov 2012
- Last updated
- 16 Jul 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Standaert DG, Rodriguez RL, Slevin JT, Lobatz M, Eaton S, Chatamra K, Facheris MF, Hall C, Sail K, Jalundhwala YJ, Benesh J. Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease. Mov Disord Clin Pract. 2017 Nov-Dec;4(6):829-837. doi: 10.1002/mdc3.12526. Epub 2017 Sep 20.
PubMed 29242809
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label, Two Part, Multicenter Study to Assess the Safety and Efficacy of Levodopa-Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects With Advanced Parkinson's Disease
- ClinicalTrials.gov ID
- NCT01736176
- Acronym / sponsor ID
- M12-920
- Conditions
- Advanced Parkinson's Disease
- Keywords
- Safety and efficacy, Advanced Parkinson's disease, levodopa-carbidopa intestinal gel,, carbidopa, levodopa, Non-Motor Symptom Scale
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 39 participants (actual)
- Lead sponsor
- AbbVie (prior sponsor, Abbott)Industry (pharma, biotech, devices)
- Study start
- Mar 2013
- Primary completion
- Mar 2015 (actual)
- Study completion
- Dec 2015 (actual)
- First posted
- 29 Nov 2012 (estimated)
- Results
- Posted 8 Feb 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to evaluate change in non-motor symptoms from baseline to Week 12 as measured by the Non-Motor Symptom Scale total score.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Levodopa-Carbidopa Intestinal Gel | Experimental | Drug: Levodopa-Carbidopa Intestinal Gel, Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J), Drug: Levodopa-carbidopa Immediate Release (LC-IR) TabletsParticipants had the PEG-J tube placement procedure performed on Study Day 1 and, at the discretion of the investigator, began initiation and titration of LCIG infusion. Dosing was determined individually. The starting total daily dose of LCIG was based solely on the daily dose of the oral levodopa taken immediately prior to Study Day 1 and was adjusted to obtain the optimal clinical response for the individual participant. Participants received treatment for up to 60 weeks; participants who completed their Week 60 visit before LCIG was commercially available had the option to extend their LCIG therapy, if in the opinion of the investigator, the participant would benefit from continued LCIG treatment. |
Who may qualify
- Ages
- 30 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Subject must have a diagnosis of idiopathic Parkinson's disease (PD) according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria
- Demonstrate persistent motor fluctuations in spite of individually optimized treatment
- Subject must experience a minimum of 3 hours "Off" time
Key exclusion criteria (3 listed)
- Subject's PD diagnosis is unclear or there is a suspicion that the subject has a Parkinsonian syndrome such as secondary Parkinsonism (e.g., caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), Parkinson-plus syndrome (e.g., Multiple System Atrophy, Progressive Supranuclear Palsy, Diffuse Lewy Body Disease, Corticobasilar Degeneration), or other neurodegenerative disease that might mimic the symptoms of PD.
- Subject has undergone neurosurgery for the treatment of Parkinson's disease
- Subject for whom the placement of a PEG-J tube for LCIG treatment is contraindicated or is considered a high risk for the PEG-J procedure according to the gastroenterology evaluation (e.g., pathological changes of the gastric wall, inability to bring the gastric wall and abdominal wall together, blood coagulation disorders, peritonitis, acute pancreatitis, paralytic ileus).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Levodopa-Carbidopa Intestinal GelAlso: Duopa, Carbidopa-levodopa enteral suspension (CLES)Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube. The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours. | Drug | Levodopa-Carbidopa Intestinal Gel |
| Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J) | Procedure or surgery | Levodopa-Carbidopa Intestinal Gel |
| Levodopa-carbidopa Immediate Release (LC-IR) TabletsAfter LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use. | Drug | Levodopa-Carbidopa Intestinal Gel |
Primary outcome
Change From Baseline to Week 12 in the Non-Motor Symptom Scale (NMSS) Total Score
Time frame: Baseline and Week 12
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; the total score is obtained by summing the item scores. The NMSS total score ranges from 0 to 360 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
37 secondary outcomes
Number of Participants Who Used Healthcare Resources During the First 4 Weeks
Time frame: Weeks 1-4
Number of Participants With Adverse Events
Time frame: Weeks 1-4 and Overall (from Week 1 through 30 days after the end of the LCIG Treatment Period; median duration of LCIG device exposure was 428 days)
Number of Participants Who Used Healthcare Resources Through Week 60
Time frame: Week 60
Change From Baseline to Week 60 in the Non-Motor Symptom Scale (NMSS) Total Score
Time frame: Baseline and Week 60
Change From Baseline in NMSS Cardiovascular Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Sleep/Fatigue Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Mood/Cognition Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Perceptual Problems/Hallucinations Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Attention/Memory Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Gastrointestinal Tract Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Urinary Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Sexual Function Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Miscellaneous Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in Mean Daily Normalized "Off" Time Based on Parkinson's Disease Diary
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in Mean Daily Normalized "On" Time Without Troublesome Dyskinesia Based on PD Diary
Time frame: Baseline and Week 12 and Week 60
Change From Baseline for Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Part I: Mentation, Behavior, and Mood Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Part II: Activities of Daily Living (ADL) Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Part III: Motor Examination Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Part IV: Complications of Therapy Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Dyskinesia Items Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Part V: Modified Hoehn and Yahr Staging Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in Parkinson's Disease Questionnaire-39 Item (PDQ-39) Summary Index
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Mobility Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Activities of Daily Living Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Emotional Well-Being Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Stigma Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Social Support Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Cognition Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Communication Domain Score
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Bodily Discomfort Domain Score
Time frame: Baseline and Week 12 and Week 60
Percentage of Participants With a Patient Global Impression of Change (PGIC) Response of Improved
Time frame: Week 12 and Week 60
Treatment Satisfaction Questionnaire Scores
Time frame: Week 12 and Week 60
Change From Baseline in Health-related Productivity
Time frame: Baseline, Week 12 and Week 60
Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Spatial Working Memory Between Errors Score at Week 12
Time frame: Baseline and Week 12
Change From Baseline in CANTAB Spatial Working Memory Strategy Score at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Controlled Oral Word Association Test (COWAT) Verbal Fluency Scores at Week 60
Time frame: Baseline and Week 60
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 29242809Standaert DG, Rodriguez RL, Slevin JT, Lobatz M, Eaton S, Chatamra K, Facheris MF, Hall C, Sail K, Jalundhwala YJ, Benesh J. Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease. Mov Disord Clin Pract. 2017 Nov-Dec;4(6):829-837. doi: 10.1002/mdc3.12526. Epub 2017 Sep 20.
Related trials for Advanced Parkinson's Disease
Not yet recruiting
Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease.
Parkinson Disease
Not yet recruitingObservational study
Longitudinal Observation of Neurodegeneration in Parkinson's Disease Using Molecular Imaging and Blood Biomarkers
Idiopathic Parkinson Disease
RecruitingPhase 2
Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS
Parkinson's Disease, Deep Brain Stimulation
Not yet recruitingPhase 1
A Phase 1 Study of NCR201 in Parkinson's Disease Patients With Prior DBS
PARKINSON DISEASE (Disorder), Cell Therapy
Active, not recruiting
Enhancing Referral Decision-making for Advanced Treatment in Parkinson's Disease Through Objective Measurements and Patient Reported Outcomes.
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Janet Benesh, BS study director
AbbVie
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Levodopa-Carbidopa Intestinal Gel, Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J) and Levodopa-carbidopa Immediate Release (LC-IR) Tablets in people with Advanced Parkinson's Disease, run by AbbVie (prior sponsor, Abbott).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 8 Feb 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline to Week 12 in the Non-Motor Symptom Scale (NMSS) Total Score (time frame: Baseline and Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01736176, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2021.